Related Experiment Video

Updated: Aug 6, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

From TGF-beta to cancer therapy

Xuemei Huang1, Chung Lee

  • 1Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

Current Drug Targets
|March 20, 2003
PubMed

Insights

This study explores using TGF-beta insensitive immune cells for cancer therapy. Making immune cells resistant to TGF-beta offers a promising strategy to overcome tumor-induced immune suppression and combat cancer.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Transforming growth factor-beta (TGF-beta) is a cytokine regulating cellular processes and physiological events.
  • While TGF-beta typically inhibits cancer cell growth, tumors can evade this by becoming insensitive and overproducing TGF-beta.
  • Tumor-derived TGF-beta promotes angiogenesis and immune suppression, hindering the host's anti-cancer defenses.

Purpose of the Study:

  • To introduce the novel concept of utilizing TGF-beta insensitive host immune cells in cancer therapy.
  • To highlight the critical role of TGF-beta in tumor progression and immune evasion.
  • To propose gene therapy as a method to confer TGF-beta insensitivity to immune cells.

Main Methods:

  • Conceptual review of TGF-beta's role in cancer immunology.
  • Discussion of tumor cell adaptation to TGF-beta.
  • Exploration of gene therapy strategies for immune cell modification.

Main Results:

  • Cancer cells develop resistance to TGF-beta's inhibitory effects.
  • Overexpression of TGF-beta by tumors leads to immune suppression and enhanced angiogenesis.
  • Host immune surveillance is compromised by tumor-derived TGF-beta.

Conclusions:

  • Modifying host immune cells to be insensitive to TGF-beta presents a viable therapeutic strategy.
  • Gene therapy offers a potential pathway to engineer these resistant immune cells.
  • This approach holds promise for developing effective cancer treatments by restoring immune function against tumors.

More Related Videos

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.